KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $19.3 billion.

  • Royalty Pharma's Liabilities and Shareholders Equity rose 723.32% to $19.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $73.5 billion, marking a year-over-year increase of 775.48%. This contributed to the annual value of $18.2 billion for FY2024, which is 1123.72% up from last year.
  • As of Q3 2025, Royalty Pharma's Liabilities and Shareholders Equity stood at $19.3 billion, which was up 723.32% from $18.3 billion recorded in Q2 2025.
  • Royalty Pharma's Liabilities and Shareholders Equity's 5-year high stood at $19.3 billion during Q3 2025, with a 5-year trough of $15.9 billion in Q3 2023.
  • Over the past 5 years, Royalty Pharma's median Liabilities and Shareholders Equity value was $17.5 billion (recorded in 2021), while the average stood at $17.3 billion.
  • In the last 5 years, Royalty Pharma's Liabilities and Shareholders Equity crashed by 1028.19% in 2023 and then surged by 1379.15% in 2024.
  • Over the past 5 years, Royalty Pharma's Liabilities and Shareholders Equity (Quarter) stood at $17.5 billion in 2021, then dropped by 4.01% to $16.8 billion in 2022, then decreased by 2.57% to $16.4 billion in 2023, then grew by 11.24% to $18.2 billion in 2024, then rose by 6.17% to $19.3 billion in 2025.
  • Its last three reported values are $19.3 billion in Q3 2025, $18.3 billion for Q2 2025, and $17.6 billion during Q1 2025.